Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5951002 | 0.84 | CHRNA7 (0.37) | NOS3NOS2NOS1CHRNA7 | |
| SCHEMBL3662212 | 0.76 | ALOX5AP (0.44) | CHRNA7TLR9TLR8TLR7 | |
| SCHEMBL20587717 | 0.75 | BCAT2 (0.33) | BCAT2 | |
| SCHEMBL30621944 | 0.75 | BCAT2 (0.33) | BCAT2 | |
| SCHEMBL1255843 | 0.74 | — | — | |
| SCHEMBL31490392 | 0.74 | — | — | |
| SCHEMBL2738305 | 0.72 | APLNR (0.38) | NOS3NOS2NOS1CHRNA7RAB9A | |
| SCHEMBL17184739 | 0.70 | KEAP1 (0.40) | CHRNA7TLR9TLR8TLR7KDM4E | |
| SCHEMBL18907030 | 0.70 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL21928710 | 0.70 | CHRNA7 (0.32) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025076284-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | DELPHIA THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| US-20240360120-A1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS, INC. | 2024-10-31 | — | — | US | disclosed |
| EP-3938358-B1 | RAD51 INHIBITORS | CYTEIR THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| CN-114072390-B | RAD51 inhibitors | 赛泰尔治疗公司 | 2024-06-11 | — | — | CN | disclosed |
| US-11932636-B2 | RAD51 inhibitors | CYTEIR THERAPEUTICS, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| WO-2023216237-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2023-11-16 | — | — | WO | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | Pardes Biosciences, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | OXFORD FINANCE LLC | 2023-05-18 | — | — | US | disclosed |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| US-20100160163-A1 | Fused heterocyclic sulfonylurea compound, herbicide containing the same, and method for controlling weed with the same | TANAKA YASUSHI | 2010-06-24 | — | — | US | disclosed |
| US-20100160163-A1 | Fused heterocyclic sulfonylurea compound, herbicide containing the same, and method for controlling weed with the same | TANAKA YASUSHI | 2010-06-24 | — | — | US | disclosed |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | NOVARTIS AG (CH) | 2010-05-27 | — | — | US | disclosed |
| US-7652051-B2 | Heterocyclic compounds and methods of use | TARGEGEN, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1466527-B1 | FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME | SUMITOMO CHEMICAL CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| CN-100349517-C | Fused heterocyclic sulfonylurea compound, herbicide containing the same and method of controlling weed with the same | SUMITOMO CHEM TAKEDA AGRO CO (JP) | 2007-11-21 | — | — | CN | disclosed |
| CN-1617666-A | Fused heterocyclic sulfonylurea compound, herbicide containing the same, and method for controlling weeds using the same | SUMITOMO CHEM TAKEDA AGRO CO (JP) | 2005-05-18 | — | — | CN | disclosed |
| US-20050032650-A1 | Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1466527-A1 | FUSED HETEROCYCLIC SULFONYLUREA COMPOUND, HERBICIDE CONTAINING THE SAME, AND METHOD OF CONTROLLING WEED WITH THE SAME | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150946-A1 | HETEROCYCLE CONTAINING STAT INHIBITORS AND COMPOSITIONS | STAT5A, STAT5B, STAT3 | NOS3 3085/4885NOS2 3496/4885NOS1 3464/4885 |
| US-20100160163-A1 | Fused heterocyclic sulfonylurea compound, herbicide containing the same, and method for controlling weed with the same | NOTUM, WEE1, DDT | NOS3 1955/4885NOS2 2417/4885NOS1 2427/4885 |
| US-20100261679-A1 | CSF-1R, Inhibitors, Compositions, and Methods of Use | CSF1R, CSF3R, MSR1 | NOS3 179/4885NOS2 192/4885NOS1 117/4885 |
| US-20050032650-A1 | Fused heterocyclic sulfonylurea compound herbicide containing the same and method of controlling weed with the same | NOTUM, WEE1, DDT | NOS3 2008/4885NOS2 2508/4885NOS1 2544/4885 |
| US-20240360120-A1 | RAD51 INHIBITORS | RAD51, MRE11, RAD54L | NOS3 4221/4885NOS2 3910/4885NOS1 3459/4885 |
| US-20100130490-A1 | CSF-1R INHIBITORS,COMPOSITIONS, AND METHODS OF USE | CSF1R, CSF3R, FLT3 | NOS3 339/4885NOS2 529/4885NOS1 291/4885 |
| US-20230212152-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTRL, CTSL, CTSV | NOS3 2342/4885NOS2 3256/4885NOS1 3945/4885 |
| US-11932636-B2 | RAD51 inhibitors | RAD51, MRE11, RAD54L | NOS3 4221/4885NOS2 3910/4885NOS1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.